NCT05854966: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Not yet recruiting | 2 | 17 | US | CPI 613, Devimistat, Metformin, Metformin pill, Blood draws, Bone marrow biopsy | Wake Forest University Health Sciences, National Cancer Institute (NCI), Cornerstone Pharmaceuticals | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma | 04/25 | 09/25 | | |
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue |
|
|
| Completed | 1/2 | 16 | US | CPI-613 + Hydroxychloroquine | Cornerstone Pharmaceuticals | Sarcoma, Clear Cell | 03/23 | 03/23 | | |
